Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 3/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301651 | 0.90 | — | — | |
| SCHEMBL12376897 | 0.89 | TSHR (0.36) | HTR1BHTR1DKDM4ERECQLTSHR | |
| SCHEMBL9349287 | 0.87 | CA12 (0.48) | KDM4ERECQLTSHRCARM1MEN1 | |
| SCHEMBL18773073 | 0.87 | TSHR (0.44) | HTR1BHTR1DKDM4ETSHRMEN1 | |
| SCHEMBL26280264 | 0.87 | TSHR (0.39) | HTR1BHTR1DKDM4ERECQLTSHR | |
| SCHEMBL23651532 | 0.87 | KDM4E (0.42) | HTR1BHTR1DKDM4ERECQLTSHR | |
| SCHEMBL8737489 | 0.87 | CA12 (0.35) | HTR1BHTR1DKDM4ERECQLMEN1 | |
| SCHEMBL21553563 | 0.87 | HTR1B (0.39) | HTR1BHTR1DPRMT3CARM1PRMT6 | |
| SCHEMBL22276504 | 0.87 | HTR1B (0.39) | HTR1BHTR1DPRMT3CARM1PRMT6 | |
| SCHEMBL22276507 | 0.87 | HTR1B (0.39) | HTR1BHTR1DPRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| EP-2438038-B1 | PROCESS FOR THE PREPARATION OF SECONDARY OR TERTIARY AMINES | HUNTSMAN CORP HUNGARY ZRT (HU) | 2016-04-20 | — | — | EP | disclosed |
| EP-2438039-B1 | A METHOD FOR SEPARATING N,N-DIALKYLBISAMINOALKYLETHER FROM MIXTURES COMPRISING N,N-DIALKYLBISAMINOALKYLETHER AND AT LEAST ONE OF N,N,N'-TRIALKYLBISAMINOALKYLETHER AND N,N,N',N'-TETRAALKYLBISAMINOALKYLETHER | HUNTSMAN CORP HUNGARY ZRT (HU) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012072441-A1 | BLOWING CATALYST | HUNTSMAN CORPORATION HUNGARY ZRT. (HU) | 2012-06-07 | — | — | WO | disclosed |
| US-20120130132-A1 | METHOD FOR SEPARATING N,N-DIALKYLBISAMINOALKYLETHER FROM MIXTURES COMPRISING N,N-DIALKYLBISAMINOALKYLETHER AND AT LEAST ONE OF N,N,N'-TRIALKYLBISAMINOALKYLETHER AND N,N,N',N'-TETRAALKYLBISAMINOALKYLETHER | HUNTSMAN INTERNATIONAL LLC | 2012-05-24 | — | — | US | disclosed |
| US-20120071622-A1 | Method for Providing a Secondary or Tertiary Amine | Huntsman Corporation Hungary ZRt (HU) | 2012-03-22 | — | — | US | disclosed |
| WO-2010139521-A1 | A METHOD FOR PROVIDING A SECONDARY OR TERTIARY AMINE | HUNTSMAN CORPORATION HUNGARY ZRT. (HU) | 2010-12-09 | — | — | WO | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HTR1B 3585/4885HTR1D 4504/4885KDM4E 4753/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | HTR1B 408/4885HTR1D 558/4885KDM4E 1310/4885 |
| US-20120071622-A1 | Method for Providing a Secondary or Tertiary Amine | HRH3, HRH4, NPR3 | HTR1B 303/4885HTR1D 1064/4885KDM4E 1925/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HTR1B 3585/4885HTR1D 4504/4885KDM4E 4753/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | HTR1B 3585/4885HTR1D 4504/4885KDM4E 4753/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HTR1B 3585/4885HTR1D 4504/4885KDM4E 4753/4885 |
| US-20120130132-A1 | METHOD FOR SEPARATING N,N-DIALKYLBISAMINOALKYLETHER FROM MIXTURES COMPRISING N,N-DIALKYLBISAMINOALKYLETHER AND AT LEAST ONE OF N,N,N'-TRIALKYLBISAMINOALKYLETHER AND N,N,N',N'-TETRAALKYLBISAMINOALKYLETHER | NCLN, NCL, DNPH1 | HTR1B 1534/4885HTR1D 2104/4885KDM4E 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.